<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370745</url>
  </required_header>
  <id_info>
    <org_study_id>G12122013 MSGEM</org_study_id>
    <nct_id>NCT02370745</nct_id>
  </id_info>
  <brief_title>Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle</brief_title>
  <acronym>Incretin</acronym>
  <official_title>Characterizing the Incretin Effect of Amino Acids (AA) and Defining the Effect of GLP-1 on Muscle Microvascular Blood Flow and Muscle Protein and Glucose Metabolism in Older Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two protocols the aims of which are:

        1. To identify age-related effects of AA on incretin secretion and whether and to what
           extent AA exhibit a true incretin effect (gut- mediated increases in plasma insulin) in
           younger individuals. (Protocol 1)

        2. To define the extra-pancreatic ''novel'', insulin independent effects of glucagon like
           peptide-1 (GLP-1) on postprandial muscle protein and glucose metabolism and
           microvascular blood flow. (Protocol 2)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol 1:

      This will explore the first aim. 8 Healthy younger volunteers will be recruited to under go 3
      arms cross over studies. Interventions will include oral and intravenous amino acids, in
      addition to intravenous GLP-1 and glucose dependent insulinotropic polypeptide (GIP).

      8 older subjects also will be recruited for comparison of the response of GI hormones to
      amino acids oral feed between young and older men.

      Therefore the total number will be recruited to perform this protocol is 16.

      Post intervention in all visits, measurements will be taken for:

      Insulin, Amino acids, GLP-1, GIP, Ghrelin and peptide YY (PYY).

      The measurable end points for this protocol are:

        1. Gut hormones levels in response to the 2 methods of AA delivery (I.V and oral)

        2. Differences in gut hormones levels between young and older subjects when AA's are
           delivered orally

      Protocol 2:

      This will explore the second aim. 16 healthy older subjects will be recruited and subdivided
      randomly into two groups to receive either post absorptive or postprandial insulin
      concentrations with or without GLP-1 at physiological ranges in a cross over fashion . During
      acute study parameters of muscle glucose and amino acids metabolism will be tested together
      with muscle microvascular recruitment and macro vascular flow in the tested leg.

      The measurable end points for this protocol are:

        1. Muscle Glucose uptake, assessed by measuring 2-deoxyglucose (2-DOG) phosphate in muscle
           biopsies

        2. Myofibrillar protein synthesis, assessed via muscle biopsy fractional synthesis rate
           (FSR)

        3. Whole Leg Muscle Protein Synthesis, assessed via Arterial-Venous difference (AV method)

        4. Whole Leg Muscle Protein Breakdown, assessed via AV method

        5. Whole Leg Net Protein Balance, assessed via AV method

        6. Muscle microvascular recruitment, assessed via microvascular contrast bubbles filling
           and refilling post destruction by ultrasound waves.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle protein and glucose metabolism</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed from muscle biopsies taken for measurement of protein synthesis and breakdown and glucose uptake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leg Microvascular blood flow</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed via contrast enhanced ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg Macrovascular blood flow</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed via ultrasound doppler scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion in response to oral and intravenous amino acids to assess their ability to exert incretin effect.</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed via serial blood draws measuring insulin level at baseline and and post intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut hormones secretion in response to amino acids in young and older people</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed via serial blood draws measuring gut hormones at baseline and post intervention.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Post absorptive insulin without GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.
The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postabsorptive insulin with GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.
The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postprandial insulin without GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.
The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postprandial insulin with GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.
The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral amino acids-Young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.
The intervention here is: 15g of mixed essential amino acid drink.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous (IV) amino acids- Young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.
The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV amino acids, GLP-1, GIP -Young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.
The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral amino acids- Older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.
The intervention in this arm: 15 gram of oral mixed essential amino acid drink</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.</description>
    <arm_group_label>Postabsorptive insulin with GLP-1</arm_group_label>
    <arm_group_label>Postprandial insulin with GLP-1</arm_group_label>
    <arm_group_label>IV amino acids, GLP-1, GIP -Young</arm_group_label>
    <other_name>Incretin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Actrapid</intervention_name>
    <description>Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1</description>
    <arm_group_label>Post absorptive insulin without GLP-1</arm_group_label>
    <arm_group_label>Postabsorptive insulin with GLP-1</arm_group_label>
    <arm_group_label>Postprandial insulin without GLP-1</arm_group_label>
    <arm_group_label>Postprandial insulin with GLP-1</arm_group_label>
    <other_name>Actrapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral amino acids</intervention_name>
    <description>Oral amino acids containing 15 g of amino acids</description>
    <arm_group_label>Oral amino acids-Young</arm_group_label>
    <arm_group_label>Oral amino acids- Older</arm_group_label>
    <other_name>mixed EAA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIP</intervention_name>
    <description>This will be co infused with GLP-1 and intravenous amino acids</description>
    <arm_group_label>IV amino acids, GLP-1, GIP -Young</arm_group_label>
    <other_name>Incretin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous amino acids</intervention_name>
    <description>This will aim to deliver iso equivalent amount to the amino acids administered orally</description>
    <arm_group_label>Intravenous (IV) amino acids- Young</arm_group_label>
    <arm_group_label>IV amino acids, GLP-1, GIP -Young</arm_group_label>
    <other_name>IV AA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - For protocol 1: i. Aged between 18-40 or 65-75 years ii. A body mass index (BMI) &gt;18 and
        &lt;28 kg/m2

        - For Protocol 2: i. Age 65-75 years ii. A body mass index (BMI) &gt;18 and &lt;28 kg/m2

        Exclusion Criteria:

          -  For protocol 1:

             i. A BMI &lt; 18 or &gt; 28 kg·m2 ii. Active cardiovascular disease: uncontrolled
             hypertension (BP &gt; 160/100), angina, heart failure (class III/IV), arrhythmia, right
             to left cardiac shunt or recent cardiac event iii. Cerebrovascular disease: previous
             stroke, aneurysm (large vessel or intracranial) iv. Respiratory disease including
             pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma or an
             forced expiratory volume in 1 minute (FEV1) less than 1.5 litre.

             v. Metabolic disease: hyper and hypo-parathyroidism, untreated hyper and
             hypothyroidism, Cushing's disease, types 1 or 2 diabetes vi. Active inflammatory bowel
             or renal disease vii. Malignancy viii. Recent steroid treatment (within 6 month), or
             hormone replacement therapy ix. Clotting dysfunction x. Musculoskeletal or
             neurological disorders xi. Family history of early (&lt;55y) death from cardiovascular
             disease

          -  For protocol 2:

        Same as protocol 1 in addition to:

        i. Overt muscle wasting i.e. muscle mass is more than 1 standard deviation below normal
        muscle or fat-free mass for age.

        ii. Taking beta-adrenergic blocking agents or non-steroidal anti-inflammatory drugs iii.
        Known sensitivity to SONOVUE or any other drug used in the study. iv. Subject deemed
        unsuitable for femoral cannulation at screening visit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Atherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iskandar Idris, DM, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Medical Sciences and Graduate Entry Medicine - School of Medicine - University of Nottingham</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Nilsson M, Holst JJ, Björck IM. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr. 2007 Apr;85(4):996-1004.</citation>
    <PMID>17413098</PMID>
  </reference>
  <reference>
    <citation>Hall WL, Millward DJ, Long SJ, Morgan LM. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr. 2003 Feb;89(2):239-48.</citation>
    <PMID>12575908</PMID>
  </reference>
  <reference>
    <citation>Wilkes EA, Selby AL, Atherton PJ, Patel R, Rankin D, Smith K, Rennie MJ. Blunting of insulin inhibition of proteolysis in legs of older subjects may contribute to age-related sarcopenia. Am J Clin Nutr. 2009 Nov;90(5):1343-50. doi: 10.3945/ajcn.2009.27543. Epub 2009 Sep 9.</citation>
    <PMID>19740975</PMID>
  </reference>
  <reference>
    <citation>Sjøberg KA, Holst JJ, Rattigan S, Richter EA, Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E355-62. doi: 10.1152/ajpendo.00283.2013. Epub 2013 Dec 3.</citation>
    <PMID>24302010</PMID>
  </reference>
  <reference>
    <citation>Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012 Apr;61(4):888-96. doi: 10.2337/db11-1073. Epub 2012 Feb 22.</citation>
    <PMID>22357961</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Incretin</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Skeletal muscle metabolism</keyword>
  <keyword>Microvascular recruitment</keyword>
  <keyword>Amino Acids</keyword>
  <keyword>Microvascular blood flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

